A global phase 3 FLAURA2 trial reported a statistically significant overall survival benefit when osimertinib was combined with platinum–pemetrexed chemotherapy versus osimertinib alone in advanced EGFR‑mutant non‑small cell lung cancer (NSCLC). The randomized study, co‑led by international investigators, compared the standard third‑generation EGFR inhibitor to the combination regimen and met its primary endpoint. The result implies a potential shift in first‑line management of EGFR‑mutant NSCLC by testing whether adding cytotoxic chemotherapy to targeted therapy extends life expectancy. Osimertinib is widely used as frontline targeted therapy; these data will feed regulatory and guideline discussions. EGFR‑mutant NSCLC refers to tumors driven by activating mutations in the epidermal growth factor receptor gene, a common targetable alteration in lung cancer.